简介：

简介：PostedonJanuary4,2017byFDAVoiceThispastyearwasanothersuccessfulyearforthenewdrugsprograminFDA’sCenterforDrugEvaluationandResearch(CDER).CDERreviewedandapproved22noveldrugs,mostofwhichhavethepotentialtoaddsignificantclinicalvalue

简介：Thedevelopmentofcancernanotherapeuticshasattractedgreatinterestintherecentdecade.Cancernanotherapeuticshaveovercomeseverallimitationsofconventionaltherapies,suchasnonspecificbiodistribution,poorwatersolubility,andlimitedbioavailability.Nanoparticleswithtunedsizeandsurfacecharacteristicsarethekeycomponentsofnanotherapeutics,andaredesignedtopassivelyoractivelydeliveranti-cancerdrugstotumorcells.Weprovideanoverviewofnanoparticle-baseddrugdeliverymethodsandcancertherapiesbasedontumor-targetingdeliverystrategiesthathavebeendevelopedinrecentyears.

简介：Background:Thesafetyandefficacyofcoronaryarterybypassgrafting(CABG)andsecond-generationdrug-elutingstents(DESs)inpatientswithcoronaryarterydisease(CAD)remaincontroversial.ThereforeweaimedtocomparetheoutcomesofCADpatientstreatedwithCABGandsecond-generationDESs.Methods:WesystematicallysearchedthePubMed,CochraneLibrary,Ovid,andElsevierdatabases.Studiescomparingsecond-generationDESswithCABGinCADpatientswereincluded.RevMan5.3wasusedtoextractandpoolthedatafromtheapplicablestudies.Results:Sixtrials(N=6604participants)wereincludedinthismeta-analysis.AmongalloftheCADpatients,second-generationDESswereassociatedwithnodifferencesintherisksofall-causedeath[riskratio(RR)1.18,95%confidenceinterval(CI)0.98–1.43,P=0.09],cardiovasculardeath(RR1.14,95%CI0.81–1.59,P=0.45),myocardialinfarction(RR1.22,95%CI0.98–1.54,P=0.08),andstroke(RR0.83,95%CI0.59–1.17,P=0.29),butincreasedtherisksofrevascularization(RR1.95,95%CI1.66–2.30,P<0.001)andmajoradversecardiacandcerebrovascularevents(RR1.72,95%CI:1.31–2.26,P<0.001)whencomparedwithCABG.Conclusions:InthetreatmentofCADpatients,second-generationDESswasnotassociatedwithincreasedrisksofall-causedeath,cardiovasculardeath,myocardialinfarction,andstroke,butincreasedtherisksofrevascularizationandmajoradversecardiacandcerebrovasculareventswhencomparedwithCABG.